Literature DB >> 22963144

Desensitization to antibiotics in children.

Josefina R Cernadas1.   

Abstract

Drug hypersensitivity reactions can occur to almost all drugs and antibiotics are among the most common cause for this kind of reactions. Drug hypersensitivity may affect any organ or system, and manifestations range widely in clinical severity from mild pruritus to anaphylaxis. In most cases, the suspected drug is avoided in the future. In case of infection, there is usually a safe antibiotic alternative. Nonetheless, in some cases, no alternative treatment exists for optimal therapy. Under these circumstances, desensitization may be performed. Drug desensitization is defined as the induction of a temporary state of tolerance to a drug which can only be maintained by continuous administration of the medication responsible for the hypersensitivity reaction. Desensitization is mainly performed in IgE-mediated reactions. Increasing doses of the implicated drug are administered over a short period of time, until the therapeutic dose is achieved and tolerated. Very few studies confined to children are found in literature. Most of them are case reports. In general, the proposed desensitization schemes are similar to those used in adults differing only in the final dose administered. The purpose of this study is to review desensitization to antibiotics in children presenting and discussing three clinical practical cases of desensitization in this age group.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22963144     DOI: 10.1111/pai.12001

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  6 in total

Review 1.  Antibiotic Allergy in Pediatrics.

Authors:  Allison Eaddy Norton; Katherine Konvinse; Elizabeth J Phillips; Ana Dioun Broyles
Journal:  Pediatrics       Date:  2018-05       Impact factor: 7.124

2.  Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III von Willebrand disease (VWD).

Authors:  Craig D Platt; Loren D'Angelo; Ellis J Neufeld; Ana Dioun Broyles
Journal:  J Allergy Clin Immunol Pract       Date:  2016-07-09

3.  Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement.

Authors:  Marek L Kowalski; Ignacio Ansotegui; Werner Aberer; Mona Al-Ahmad; Mubeccel Akdis; Barbara K Ballmer-Weber; Kirsten Beyer; Miguel Blanca; Simon Brown; Chaweewan Bunnag; Arnaldo Capriles Hulett; Mariana Castells; Hiok Hee Chng; Frederic De Blay; Motohiro Ebisawa; Stanley Fineman; David B K Golden; Tari Haahtela; Michael Kaliner; Connie Katelaris; Bee Wah Lee; Joanna Makowska; Ulrich Muller; Joaquim Mullol; John Oppenheimer; Hae-Sim Park; James Parkerson; Giovanni Passalacqua; Ruby Pawankar; Harald Renz; Franziska Rueff; Mario Sanchez-Borges; Joaquin Sastre; Glenis Scadding; Scott Sicherer; Pongsakorn Tantilipikorn; James Tracy; Vera van Kempen; Barbara Bohle; G Walter Canonica; Luis Caraballo; Maximiliano Gomez; Komei Ito; Erika Jensen-Jarolim; Mark Larche; Giovanni Melioli; Lars K Poulsen; Rudolf Valenta; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2016-10-12       Impact factor: 4.084

Review 4.  Immediate and Delayed Hypersensitivity Reactions to Beta-Lactam Antibiotics.

Authors:  Ellen Minaldi; Elizabeth J Phillips; Allison Norton
Journal:  Clin Rev Allergy Immunol       Date:  2021-11-12       Impact factor: 8.667

5.  Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa.

Authors:  Ezgi Ulusoy Severcan; Nursen Cigerci Gunaydin; Hamiyet Hekimci Ozdemir; Figen Gulen; Kaan Kavakli; Remziye Tanac; Esen Demir
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-09       Impact factor: 0.885

6.  Drug desensitization in allergic children.

Authors:  Silvia Caimmi; Carlo Caffarelli; Francesca Saretta; Lucia Liotti; Giuseppe Crisafulli; Fabio Cardinale; Paolo Bottau; Francesca Mori; Fabrizio Franceschini; Roberto Bernardini; Gian Luigi Marseglia
Journal:  Acta Biomed       Date:  2019-01-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.